

1 Title: Heparin Does Not Regulate Circulating Human PCSK9

2

3 Authors: Vivian Q. Xia^{1,2}, Chui Mei Ong^{3,4}, Lucas S. Zier^{1,2}, John S. MacGregor^{1,2}, Alan H. B.

4 Wu^{3,4}, John S. Chorba^{*,1,2}

5

6 Affiliations:

7 ¹Division of Cardiology, Zuckerberg San Francisco General Hospital

8 ²Department of Medicine, University of California San Francisco

9 ³Clinical Chemistry Laboratory, Zuckerberg San Francisco General Hospital

10 ⁴Department of Laboratory Medicine, University of California San Francisco

11

12 * Correspondence to: john.chorba@ucsf.edu

13

14 Abstract

15 *Background:* PCSK9 chaperones the hepatic low-density lipoprotein receptor (LDLR) for
16 lysosomal degradation, elevating serum LDL cholesterol and increasing the risk of
17 atherosclerotic heart disease. Though the major effect on the hepatic LDLR comes from
18 secreted PCSK9, the details of PCSK9 reuptake into the hepatocyte remain unclear. In both
19 tissue culture and animal models, heparan sulfate proteoglycans (HSPGs) on hepatocytes act
20 as co-receptors to promote PCSK9 reuptake. We hypothesized that if this PCSK9:HSPG
21 interaction is important in humans, disrupting the interaction with unfractionated heparin (UFH)
22 would acutely displace PCSK9 from the liver and increase plasma PCSK9.

23 *Methods:* We obtained remnant plasma samples from 160 subjects undergoing cardiac
24 catheterization before and after administration of intravenous UFH. PCSK9 levels were
25 determined using a commercial ELISA.


26 *Results:* Median plasma PCSK9 concentrations were 113 ng/ml prior to UFH and 119 ng/ml
27 afterwards. This difference was not significantly different ($p = 0.83$, 95% CI of difference: -6.23
28 to 6.31 ng/ml). Tests for equivalence provided 95% confidence that UFH administration would
29 not raise PCSK9 levels by more than 4.7% of the baseline value. No predefined subgroups
30 exhibited an effect of UFH on circulating PCSK9.

31 *Conclusion:* Administration of UFH does not result in a clinically meaningful effect on circulating
32 PCSK9 in humans. These results suggest that disruption of the PCSK9:HSPG interaction does
33 not affect PCSK9 reuptake into the liver. Further, they cast doubt on the clinical utility of
34 disrupting the PCSK9:HSPG interaction as a therapeutic strategy for PCSK9 inhibition.

35

36 Graphical Abstract

37



38

39

40

41 Clinical Perspective

42

43 *What is new?*

- 44
- 45 • Prior tissue culture and animal data suggest that PCSK9 interacts with hepatic heparan sulfate proteoglycans to enter the liver and raise cholesterol levels
 - 46 • We found no evidence that heparin, a competitive inhibitor of heparan sulfate proteoglycans, acutely affects PCSK9 in humans
- 47

48

49 *What are the clinical implications?*

- 50
- 51 • Heparin is unlikely to be successfully repurposed as a PCSK9 inhibitor
- 52

52 Main Text

53

54 PCSK9 chaperones the hepatic low-density lipoprotein receptor (LDLR) for lysosomal
55 degradation, elevating serum LDL cholesterol and increasing the risk of atherosclerotic heart
56 disease¹. Though the major effect on the hepatic LDLR comes from secreted PCSK9², the
57 details of PCSK9 reuptake into the hepatocyte remain unclear. In both tissue culture and animal
58 models, heparan sulfate proteoglycans (HSPGs) on hepatocytes bind to an arginine-rich region
59 on the PCSK9 prodomain to promote PCSK9 reuptake^{3,4}. However, to date, the PCSK9:HSPG
60 interaction has not been directly evaluated in humans. We hypothesized that if this interaction is
61 important, disrupting it with unfractionated heparin (UFH) would acutely displace PCSK9 from
62 the liver and increase plasma PCSK9. We therefore leveraged remnant blood samples from
63 patients undergoing cardiac catheterization and short-term anticoagulation with intravenous (IV)
64 UFH in the Heparin Blockade of PCSK9 (“HepBlock9”) study (Fig. 1A). To our surprise, we
65 observed no difference in circulating PCSK9 after UFH administration, suggesting that heparin
66 is unlikely to be successfully repurposed for PCSK9 inhibition.

67
68 In a protocol approved with a waiver of informed consent by the Institutional Review Board of
69 the University of California, San Francisco (UCSF, CHR #18-26734), we targeted a sample size
70 of 150 subjects for 80% power at $\alpha = 0.05$ (two-tailed) to detect a 4 ng/ml (7%) change in
71 PCSK9⁵. This was a conservative calculation given the 25% reduction in PCSK9 observed upon
72 PCSK9:HSPG disruption in animal models³. We then collected 180 paired pre- and post-UFH
73 remnant plasma samples, excluding 20 subjects for unclear records of UFH administration, a
74 prolonged (> 8 hr) delay in sample collection, recent heparin use, or evidence of impaired liver
75 function. This left us with 160 subjects available for analysis, who represented a predominantly
76 male (69%) but ethnically diverse cohort (74% non-White) with the expected high prevalence of
77 atherosclerosis (74%), statin use (70%), and obstructive coronary disease (40%).

78
79 We then measured plasma PCSK9 concentrations using a commercial ELISA (Abcam)
80 compatible with our collection strategy and reviewed the associated medical records. Median
81 PCSK9 concentrations were 113 ng/ml prior to UFH and 119 ng/ml after, with no significant
82 difference between the matched samples ($p = 0.83$, Fig. 1B&C). Equivalence testing provided
83 95% confidence that the rise in PCSK9 from UFH was no more than 5.35 ng/ml, or 4.7% of the
84 baseline. Because several homeostatic mechanisms regulate circulating PCSK9⁵, we also
85 evaluated the effect of IV UFH on circulating PCSK9 after stratifying by sex, age, race, ethnicity,
86 burden of atherosclerosis, presentation of acute coronary syndrome (ACS), statin use, non-HDL
87 cholesterol, renal function, and UFH dose. However, we failed to identify any subgroup that
88 displayed a significant response (Fig. 1D). We conclude from these data that administration of
89 IV UFH does not raise PCSK9 concentrations acutely.

90
91 We focused on bolus administration of UFH because the reported half-life of circulating PCSK9
92 is only 5 minutes². To assess whether longer UFH treatments are required to disrupt PCSK9

93 uptake, we compared baseline PCSK9 concentrations in our main cohort to the 12 subjects
94 excluded because of prior treatment with heparin-like products, but found no significant
95 difference ($p = 0.24$, Fig. 1E&F). We also measured PCSK9 concentrations in 22 separate
96 patients anticoagulated with continuous IV UFH. Median PCSK9 concentrations in the paired
97 samples were no different after either a 6 hr ($p > 0.99$, Fig. 1G) or 24 hr infusion ($p = 0.55$, Fig.
98 1G). Because this cohort displayed a wide distribution of baseline PCSK9 concentrations, we
99 also explored the effects on the fractional change in PCSK9 at both timepoints, but again found
100 no significant difference ($p = 0.97$ for 6 hrs, $p = 0.18$ for 24 hrs, Fig. 1H).

101
102 Together, our data support the null hypothesis: that administration of therapeutic UFH does not
103 disrupt PCSK9 reuptake or affect circulating PCSK9 concentrations. Our results highlight the
104 importance of assessing physiologic questions in humans to assess their clinical relevance,
105 given the observations on the PCSK9:HSPG interaction in prior models^{3,4}. The strengths of our
106 study include 1) direct measurements in human subjects, without need for an experimental
107 animal model, 2) the clinical relevance to potential drug repurposing, even if the answer is
108 negative, 3) temporal observations to draw causal inferences, 4) the diverse ethnic population of
109 our sample, improving the generalizability of our findings, and 5) the use of subjects as their
110 own controls to minimize confounding from the substantial variability in PCSK9 concentrations
111 among individuals. Our study is limited by 1) a reliance on static measurements, leaving us
112 unable to directly assess PCSK9 kinetics or shifts between body compartments, 2) a sample
113 size powered for our main hypothesis but not necessarily subgroup analyses, and 3) the focus
114 on acute UFH administration, which limits our conclusions regarding long-term HSPG blockade.
115 Given the relative infrequency of PCSK9 variants, we also cannot comment on the role of the
116 PCSK9:HSPG interaction in certain genetic backgrounds, which may yet remain important⁴.

117

118 In conclusion, we found no evidence that heparin acutely interferes with PCSK9 uptake, casting
119 doubt on the clinical utility of disrupting the PCSK9:HSPG interaction as a potential strategy to
120 inhibit PCSK9 function.

121

122

123 *Acknowledgments:* We thank the UCSF cardiology fellows and nursing staff of the ZSFG
124 cardiac catheterization laboratory for preservation of remnant samples.

125

126 *Funding:* This work was supported by the NIH/NHLBI (K08 HL124068, R03 HL145259, R01
127 HL146404, and R01 HL159457), a Pfizer ASPIRE Cardiovascular Award, the Harris Fund, the
128 Research Evaluation and Allocation Committee of the UCSF School of Medicine, all to J.S.C.

129

130 *Author contributions:* Overall study design: J.S.C; Supervision of preservation of remnant
131 samples: L.S.Z, J.S.M.; Storage and processing of remnant samples: C.M.O, A.H.B.W.;
132 Determination of PCSK9 concentrations: V.Q.X, J.S.C; Data analysis: V.Q.X, J.S.C; Manuscript
133 preparation: J.S.C; Critical review and revision of the manuscript: All authors.

134

135 *Competing interests:* J.S.C. has received consulting fees from Gilde Healthcare and Eko.

136

137 *Data availability:* Additional data and materials requests are available from the corresponding
138 author via material transfer agreement, subject to IRB review.

139

140

141 References

142

143 1. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: A Key Modulator of Cardiovascular

- 144 Health. *Circ Res*. 2014;114(6):1022-1036. doi:10.1161/CIRCRESAHA.114.301621
- 145 2. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces
146 liver LDL receptors in mice. *J Lipid Res*. 2008. doi:10.1194/jlr.M800027-JLR200
- 147 3. Gustafsen C, Olsen D, Vilstrup J, et al. Heparan sulfate proteoglycans present PCSK9 to
148 the LDL receptor. *Nat Commun*. 2017;8(1):503. doi:10.1038/s41467-017-00568-7
- 149 4. Galvan AM, Chorba JS. Cell-associated heparin-like molecules modulate the ability of
150 LDL to regulate PCSK9 uptake. *J Lipid Res*. 2019;60(1):71-84. doi:10.1194/jlr.M087189
- 151 5. Lakoski SG, Lagace T a, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic
152 determinants of plasma PCSK9 levels. *J Clin Endocrinol Metab*. 2009;94(7):2537-2543.
153 doi:10.1210/jc.2009-0141


154

155

156

157

158



159

160

161 **Figure 1: HepBlock9 Study.** A) Schematic of study. Remnant blood samples before and after

162 heparin administration in subjects undergoing cardiac catheterization were tested for PCSK9

163 concentrations. B) Plasma PCSK9 concentrations in study subjects before (black) and after

164 (pink) IV UFH administration. C) Difference in plasma PCSK9 concentrations before and after IV
165 UFH in total subjects. Source data is the same as from B. D) Difference in plasma PCSK9
166 concentrations before and after IV UFH in subjects stratified by sex, age, race, ethnicity,
167 obstructive CAD, atherosclerosis, ACS presentation, percutaneous coronary intervention (PCI),
168 statin use, serum non-HDL cholesterol, serum creatinine, or heparin dose. E) Baseline (pre-
169 UFH) plasma PCSK9 concentrations in study subjects (after exclusions, black) and subjects
170 excluded due to prior UFH or low-molecular-weight heparin (LMWH) administration (purple).
171 Mann-Whitney test shown. F) Difference in PCSK9 concentrations before and after IV UFH in
172 subjects excluded due to prior UFH or LMWH administration. G) Plasma PCSK9 concentrations
173 before (black) or after 6 (teal) or 24 (light blue) hr infusions of IV UFH. Note the discontinuous Y
174 axis. H) Fractional difference in plasma PCSK9 concentrations before and after IV UFH
175 infusions. Source data is the same as from G. *All panels*) Unless otherwise noted, Wilcoxon
176 signed-rank tests shown, comparing matched-pairs between groups or to a hypothetical median
177 of 0, with Holm-Sidak corrections for multiple hypothesis testing when appropriate. n = number
178 of subjects in each group, ns = non-significant at adjusted $p > 0.05$.